How to avoid the impact of environmental mycobacteria towards the efficacy of BCG vaccination against tuberculosis?
Bacillus Calmette–Guérin (BCG) remains the only widely used vaccine against tuberculosis (TB). Consistent efficacy has been proved in infants but not in adults from developing countries. Epidemiological and experimental studies have pointed out that, prior exposure to prevailing environmental mycoba...
Main Author: | Om Parkash |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | International Journal of Mycobacteriology |
Subjects: | |
Online Access: | http://www.ijmyco.org/article.asp?issn=2212-5531;year=2014;volume=3;issue=1;spage=1;epage=4;aulast=Parkash |
Similar Items
-
Vaccination against M. tuberculosis – what next after BCG?
by: Marek Fol, et al.
Published: (2011-01-01) -
Tokyo-172 BCG Vaccination Complications, Taiwan
by: Ruwen Jou, et al.
Published: (2009-09-01) -
Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations
by: Shalini Pooransingh, et al.
Published: (2020-03-01) -
Features of the development of tuberculosis in children not vaccinated with BCG
by: O. M. Raznatovska, et al.
Published: (2018-07-01) -
TUBERCULOSIS VACCINES: CURRENT STATE AND FUTURE DIRECTIONS
by: Olimpia Nicolaescu
Published: (2017-03-01)